Abstract

Pyrogen content is a key quality feature that must be checked in all injectable products, including vaccines. Four tests are currently available in the European Pharmacopoeia to monitor pyrogen/endotoxin presence: the rabbit pyrogen test (RPT), the bacterial endotoxin test, the recombinant factor C test, and the monocyte activation test (MAT). Here, we explored the possibility to replace the RPT with the MAT in the quality control of a vaccine against tick-borne encephalitis virus (TBEV). The testing was carried out using cryopreserved peripheral blood mononuclear cells as cell source. IL-6 release was selected as readout for the detection of both endotoxin and non-endotoxin contaminants. MAT applicability for pyrogen testing of the TBEV vaccine was assessed through preparatory tests and resulted in the establishment of a very sensitive assay (limit of detection (LOD) = 0.04 EU/mL; sensitivity = 0.1 EU/mL). Both quantitative Method A and semiquantitative Method B were used for data analysis. Our studies revealed that for a vaccine without intrinsic pyrogenicity, such as that against TBEV, sensitivity (the lowest endotoxin value of the standard curve) should be used instead of LOD to define a stable maximum valid dilution of the product. In conclusion, we describe the challenges of MAT implementation for anti-TBEV vaccine following the current Ph. Eur. chapter 2.6.30 and propose a re-evaluation of the validity criteria of Methods A and B in order to set a semi-quantitative or limit test suitable for those products for which a reference lot comparison analysis is not applicable or favorable.

Highlights

  • Tick-borne encephalitis (TBE) is an illness caused by tick-borne encephalitis virus (TBEV) infection, whose clinical manifestations range from febrile illness to highly aggressive downstream neurological symptoms (Ruzek et al, 2019)

  • 3.1 Comparison of TNF-α, interleukin 6 (IL-6) and IL-1β as monocyte activation test (MAT) read-outs for the detection of both endotoxin and non-endotoxin contaminants To define which cytokine is the most appropriate read-out in our setting, a simultaneous cytokine measurement was performed on peripheral blood mononuclear cells (PBMC) supernatants stimulated with both endotoxin and non-endotoxin stimuli

  • PBMC were treated with RSE, Fig. 1: Pro-inflammatory cytokine release in PBMC cultures stimulated with endotoxin and non-endotoxin contaminants Peripheral blood mononuclear cells (PBMC) were stimulated with RSE (A) (0.2 and 0.4 EU/mL), R848 (B) (0.15 and 0.3 mg/mL), FSL-1 (C) (0.02 and 0.04 ng/mL) or left untreated, and TNF-α, IL-6 and IL-1β production was assessed in culture supernatants by cytometric bead assay

Read more

Summary

Introduction

Tick-borne encephalitis (TBE) is an illness caused by tick-borne encephalitis virus (TBEV) infection, whose clinical manifestations range from febrile illness to highly aggressive downstream neurological symptoms (Ruzek et al, 2019). Two European vaccines have been produced: FSME-IMMUN (Pfizer, USA), prepared from the Neudoerfl strain of the European subtype (Barrett et al, 2003), and Encepur (GSK), based on the Karlsruhe (K23) strain (Harabacz et al, 1992; Girgsdies and Rosenkranz, 1996). These vaccines have been used for more than 30 years and are highly effective in preventing TBE (Barrett et al, 2003)

Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.